Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
5.00
+0.09 (1.94%)
Apr 29, 2026, 12:25 PM EDT - Market open
Aptevo Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -25.97 | -24.13 | -17.41 | 8.03 | -28.46 | |
| Depreciation & Amortization | 0.24 | 0.35 | 0.57 | 0.9 | 1.14 | |
| Loss (Gain) From Sale of Assets | - | - | - | 0.05 | 0 | |
| Stock-Based Compensation | 0.1 | 1.07 | 2.19 | 1.8 | 1.64 | |
| Other Operating Activities | 1.09 | 1.1 | 0.01 | -33.94 | 6.64 | |
| Change in Accounts Receivable | - | - | 2.5 | 1.16 | -1.3 | |
| Change in Accounts Payable | -0.16 | -1.02 | 0.52 | -0.39 | -1.92 | |
| Change in Other Net Operating Assets | -0.89 | -1.16 | -0.11 | 1.37 | 0.56 | |
| Operating Cash Flow | -25.59 | -23.79 | -11.73 | -21.02 | -21.68 | |
| Capital Expenditures | - | - | - | -0.03 | -0.71 | |
| Investing Cash Flow | - | - | - | -0.03 | -0.71 | |
| Long-Term Debt Repaid | - | - | -3.47 | -12.27 | -10.55 | |
| Net Debt Issued (Repaid) | - | - | -3.47 | -12.27 | -10.55 | |
| Issuance of Common Stock | 38.5 | 15.13 | 9.48 | 6.93 | 11.44 | |
| Repurchase of Common Stock | - | -0 | -0.01 | -0 | - | |
| Other Financing Activities | - | 0.47 | - | 2.72 | 25.27 | |
| Financing Cash Flow | 38.5 | 15.6 | 6 | -2.62 | 26.16 | |
| Net Cash Flow | 12.91 | -8.19 | -5.73 | -23.67 | 3.77 | |
| Free Cash Flow | -25.59 | -23.79 | -11.73 | -21.05 | -22.39 | |
| Free Cash Flow Margin | - | - | - | -676.01% | -182.17% | |
| Free Cash Flow Per Share | -81.11 | - | - | - | - | |
| Levered Free Cash Flow | -15.88 | -15.52 | -11.7 | -29.32 | 2.01 | |
| Unlevered Free Cash Flow | -15.88 | -15.52 | -11.7 | -29.32 | 2.01 | |
| Change in Working Capital | -1.05 | -2.18 | 2.91 | 2.14 | -2.66 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.